Guillain Barre Syndrome
Guillain-Barré syndrome is a rare condition that causes the immune system to attack the nerves outside of the brain and spinal cord. It is characterized by numbness, tingling, weakness, or paralysis in the legs, arms, breathing muscles, and face. It can affect all ages.
|Copyright © Nucleus Medical Media, Inc.|
Guillain-Barré syndrome is more common in men, and in the those aged 15-35 years and 60-75 years old. Other factors that increase your chance of Guillain-Barré syndrome may include:
- Recent gastrointestinal or respiratory infection by viruses or bacteria
- The swine flu vaccine given from 1976-1977 was linked to excess cases of Guillain-Barré syndrome. (Since then, influenza virus vaccines have been associated with only a marginally increased risk of Guillain-Barré syndrome.)
- Recent surgery
- History of lymphoma , systemic lupus erythematosus , or HIV infection
The first symptoms of Guillain-Barré syndrome include:
- Pain—the lower back pain is the most common complaint
- Progressive muscle weakness on both sides of the legs, arms, and face
- Prickly, tingling sensations, usually in the feet or hands
- Loss of normal reflexes
Symptoms may develop over a period of hours, days, or weeks. They will vary in severity from minimal to total paralysis including respiratory weakness. The symptoms grow progressively worse. Most people experience the greatest weakness during the second or third week.
Related complications include:
- Facial weakness
- Blood pressure instability
- Heart rate changes
- Sweating abnormalities
- Heart arrhythmias
- Urinary/gastrointestinal dysfunction
- Breathing difficulty
Most people fully recover, but others may have residual symptoms, or permanent or disabling problems.
Treatment aims to reduce the body’s autoimmune response and decrease complications that result from immobility. Hospitalization is important because symptoms may rapidly become more severe, including respiratory failure, heart arrhythmias, and blood pressure instability.
Common treatments include:
During plasmapheresis, blood is removed from your body and passed through a machine that separates blood cells. The separated cells are then returned to your body with new plasma. This procedure may help shorten the course and severity of Guillain-Barré syndrome.
High-dose Immunoglobulin Therapy
Intravenous infusion with immunoglobulin (IVIg) may help reduce the severity of a Guillain-Barré attack. Immunoglobulins are proteins that are naturally produced by the body’s immune system.
In some cases, muscles necessary for breathing become paralyzed. This is treated with immediate emergency support from a mechanical ventilator.
Your doctor may advise
- Over-the-counter or prescription pain relievers
- Antiseizure medications
This content is reviewed regularly and is updated when new and relevant evidence is made available. This information is neither intended nor implied to be a substitute for professional medical advice. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with questions regarding a medical condition.
Edits to original content made by Denver Health.
Copyright © EBSCO Information Services
All rights reserved.
a (Acute Inflammatory Demyelinating Polyradiculoneuropathy; Acute Inflammatory Demyelinating Polyneuropathy; Acute Idiopathic Polyneuritis; Acute Inflammatory Polyneuropathy; Acute Autoimmune Neuropathy; Idiopathic Polyneuritis; AIDP)
Guillain-Barré Syndrome Foundation International http://www.gbs-cidp.org
National Institute of Neurological Disorders and Stroke http://www.ninds.nih.gov
Canadian Institute for Health Information http://www.cihi.ca
Health Canada http://www.hc-sc.gc.ca
Amyotrophic lateral sclerosis. EBSCO DynaMed Plus website. Available at: http://www.dynamed.com/topics/dmp~AN~T116744/Amyotrophic-lateral-sclerosis-ALS . Updated July 25, 2016. Accessed September 23, 2016.
Guillain-Barre syndrome. EBSCO DynaMed Plus website. Available at: Available at: http://www.dynamed.com/topics/dmp~AN~T116758/Guillain-Barre-syndrome . Updated September 10, 2016. Accessed September 23, 2016.
Vucic S, Kiernan MC, Cornblath DR. Guillain-Barre: an update. J Clinical Neuroscience. 2009;16(6):733-741.